Business Context and Reporting Period
This Form 8-K is a current report filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on April 21, 2010, regarding events occurring on April 19, 2010. The filing discloses the execution of Amended and Restated Employment Agreements with two key executives: Frank L. Jaksch, Jr. (Co-Chairman, CEO, and President) and Thomas Varvaro (CFO, Secretary, and Director).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Material Changes
The primary material change is the amendment of employment contracts for the CEO and CFO, effective April 19, 2010. Key changes include:
- Frank L. Jaksch, Jr.:
- Base salary increased from $175,000 to $225,000 (subject to a $50,000 increase upon stock exchange listing).
- Annual cash bonus target increased to up to 40% of base salary.
- Granted two option grants totaling 800,000 shares of Common Stock.
- Term extended to three years with automatic one-year renewals.
- Thomas Varvaro:
- Base salary increased from $130,000 to $175,000 (subject to a $50,000 increase upon stock exchange listing).
- Annual cash bonus target set at up to 30% of base salary.
- Granted two option grants totaling 400,000 shares of Common Stock.
- Term extended to three years with automatic one-year renewals.
Guidance, Outlook, and Risks
The filing does not provide financial guidance or operational outlook. However, it outlines significant financial contingencies related to executive severance:
- Severance Triggers: Both executives are entitled to enhanced severance packages in the event of termination without "Cause," termination for "Good Reason" (including material change in duties or location), or "Cessation of Business."
- Severance Value: In the event of termination without cause and signing a separation agreement, executives could receive up to 24 months of base salary, full vesting of unvested stock, and the Maximum Annual Bonus.
- Good Reason Definition: Includes specific triggers such as the termination of the CEO (for Mr. Varvaro) or a relocation of the workplace more than 50 miles from the executive's residence.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the dilution impact of the 1.2 million new stock options granted.
- Review the company's current cash position to determine its ability to fund potential severance obligations (up to 24 months of salary plus bonuses) if triggered.
- Confirm the status of the company's Common Stock listing, as this triggers an additional $50,000 salary increase for both executives.
- Examine the full text of Exhibits 10.1 and 10.2 for specific definitions of "Cause" and "Good Reason" to understand the likelihood of severance payouts.